CASC3 and Miyoshi myopathy: Thus, the combination of the NRF2 inhibitor all-trans-retinoic acid (ATRA) with BTZ re-sensitizes MM cells resistant to BTZ in preclinical models, suggesting a possible dependency on an increased de novo biosynthesis of proteasomes [41].